Keyphrases
COVID-19
83%
Asthma
83%
Primary Antibody Deficiency
66%
Replacement Product
53%
Immunoglobulin Replacement
53%
Antibody Deficiency
47%
Neutralizing Activity
46%
Caregivers
44%
Omicron Variant
38%
Antibody Response
38%
Booster Vaccination
33%
IgG1
33%
Memory B-cell Response
33%
Allergic Rhinitis
33%
Inhaled Corticosteroid Therapy
33%
Latino
33%
Comparative Effectiveness Trial
33%
Stakeholder Engagement
33%
Symptom-based
33%
Paediatric Physician
33%
MRNA Vaccine
33%
Sexual Assault
33%
AIDS/HIV
33%
Pre-exposure Prophylaxis (PrEP)
33%
African American
33%
Provider Perspectives
33%
SARS-CoV-2 Infection
33%
Immunoglobulin
22%
Anti-spike
20%
Drug Allergy
16%
Environmental Allergies
16%
Allergic Rhinoconjunctivitis
16%
Immunodeficiency
16%
Urticaria
16%
Food Allergy
16%
B Cell Response
14%
Primary Vaccination
14%
Receptor-binding Domain
13%
Titer
13%
Antireceptor
13%
Protective Behavior
12%
Healthy Donors
12%
Engagement Process
11%
Immunoglobulin Prophylaxis
11%
Hispanic or Latino
11%
Perceived Challenges
11%
Power Dynamics
11%
Uncontrolled Asthma
11%
Perceived Benefits
11%
Patient-Centered Outcomes Research Institute (PCORI)
11%
Immunology and Microbiology
Severe Acute Respiratory Syndrome Coronavirus 2
100%
Humoral Immune Deficiency
66%
Intravenous Immunoglobulin
55%
Omicron Coronavirus Variant
41%
Immunodeficiency
38%
Antibody Response
38%
Immunoglobulin G1
33%
Memory B Cell
33%
Drug Hypersensitivity
33%
Asthma
33%
Food Allergy
33%
Environmental Allergy
33%
Allergic Rhinitis
33%
Spike
20%
COVID-19
18%
Receptor Binding
16%
B Cell
14%
Titer
11%
Immune Response
9%
T Cell
9%
Antibody Titer
9%
Immunodeficiency
7%
Neutralizing Antibody
5%
Fc Receptor
5%
Humoral Immunity
5%
Hepatitis Delta Virus
5%
Virus
5%
Medicine and Dentistry
Memory B Cell
33%
Pediatrics
33%
Humoral Immune Deficiency
33%
Severe Acute Respiratory Syndrome Coronavirus 2
33%
Corticosteroid Therapy
33%
Human Immunodeficiency Virus
33%
Post-Exposure Prophylaxis
33%
Immunoglobulin G1
33%
Asthma
33%
Adolescence
33%
Pediatrician
25%
B Cell
14%
T-Cell Response
14%
Infection
10%
Immune Response
9%
COVID-19 Vaccine
9%
Messenger RNA
9%
Moderate Persistent Asthma
8%
Controlled Clinical Trial
8%
Patient Communication
8%
Health Care Cost
8%
Bronchodilating Agent
8%
Prevalence
5%
